"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 3 | 3 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 7 | 7 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 12 | 12 |
| 2014 | 0 | 8 | 8 |
| 2015 | 0 | 9 | 9 |
| 2016 | 0 | 10 | 10 |
| 2017 | 1 | 10 | 11 |
| 2018 | 0 | 9 | 9 |
| 2019 | 0 | 12 | 12 |
| 2020 | 0 | 12 | 12 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 7 | 7 |
| 2025 | 0 | 6 | 6 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study. Inflamm Bowel Dis. 2026 Apr 01; 32(4):702-710.
-
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant. 2026 May; 61(5):591-600.
-
Evaluation of ravulizumab trough levels in pediatric complement-mediated hemolytic uremic syndrome in remission. Pediatr Nephrol. 2026 Jun; 41(6):1753-1760.
-
TNF antagonists withdrawal is not advised in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis of randomized controlled trials. Int J Colorectal Dis. 2025 Dec 02; 40(1):245.
-
Association of Primary Language With Treatment and Outcomes in Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2025 Aug 01; 16(8):e00868.
-
Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Sep; 43(25):2766-2771.
-
A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease. J Crohns Colitis. 2025 May 08; 19(5).
-
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31; 12(1).
-
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multicenter Study. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2281-2291.e4.
-
Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care. Chest. 2025 Apr; 167(4):956-974.